Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
Dusp4 在乳腺癌中的作用:肿瘤抑制生物学和治疗策略
基本信息
- 批准号:9044055
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2016-04-29
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAffectApoptosisApoptoticAutomobile DrivingBioinformaticsBiologicalBiologyBreastBreast Cancer CellBreast Cancer PatientBreast Cancer TreatmentBreast Cancer therapyCell LineCellsChemotherapy-Oncologic ProcedureCisplatinClinicalClinical TrialsCytotoxic ChemotherapyDataDependenceDevelopmentDiagnosisDoxorubicinDrug TargetingDrug resistanceERBB2 geneEducational workshopEpigenetic ProcessEstrogen ReceptorsExperimental ModelsFacultyFeedbackFrequenciesFutureGene Expression ProfileGene TargetingGenesGeneticGenetically Engineered MouseGenomeGenomicsGoalsHumanHuman ResourcesInstitutionKnowledgeLearningLibrariesMAP Kinase GeneMAPK3 geneMAPK8 geneMEKsMalignant NeoplasmsMammary NeoplasmsMass Spectrum AnalysisMediatingMediator of activation proteinMentorsMethodsMethylationMitogen-Activated Protein Kinase InhibitorModelingMolecularMolecular TargetOutcomePathway interactionsPatientsPhasePhenotypePhosphoric Monoester HydrolasesPopulationPositioning AttributePublishingRecordsRegulationResearchResearch PersonnelResistanceResourcesRoleSignal PathwaySignal TransductionSmall Interfering RNASpecificityStructureTestingTherapeuticTherapeutic AgentsTrainingTraining SupportTraining and EducationTumor Suppressor GenesTumor Suppressor ProteinsUniversitiesWomanWorkXenograft ModelXenograft procedureanticancer researchbasebiological researchcancer stem cellcareercareer developmentchemotherapeutic agentchemotherapyclinically relevantdocetaxelimprovedin vivo Modelinhibitor/antagonistlecturesmalignant breast neoplasmmouse modelneoplastic cellnew therapeutic targetnovelpromoterrestorationscreeningskillstherapeutic targettherapy resistanttriple-negative invasive breast carcinomatumor
项目摘要
PROJECT SUMMARY/ABSTRACT
The goals of this Pathway to Independence Career Development Proposal are to request support for training to
develop expertise in experimental models of breast cancer while addressing a fundamental gap in knowledge
that could have a significant impact on the treatment of breast cancer patients. K99/R00 support during this
transitional phase of my career will be integral to my successful development as an independent investigator at
a top-tier research institution. The training plan outlined herein will take advantage of the extensive resources
available at Vanderbilt University as well as key senior personnel with track records of scientific excellence to
serve as mentors and collaborators.
As part of my pathway to independence I have assembled a mentoring team at Vanderbilt to provide career
development advice and scientific direction. Didactic seminars, lectures, and workshops provided by Vanderbilt
and the Biological Research Education and Training (BRET) office will provide structured support for this
guidance and will help further prepare me for an independent faculty position. A technical workshop offered by
Jackson Labs on the Experimental Models of Human Cancer as well as two workshops in Bioinformatics will
be taken during the earlier phase of this proposal in order to enhance scientific and technical knowledge on
genetically engineered mouse models and to expand my expertise and skills in Bioinformatics, both major
features of the work outlined herein.
The scientific portion of this proposal focuses on experimentally and mechanistically testing the potential role of
DUSP4 as a mediator of drug resistance in breast cancer. DUSP4 is a dual-specificity phosphatase with
activity against ERK1/2 and JNK1/2, key signaling components of the MAPK pathways. We have previously
shown that DUSP4 loss, in part by epigenetic silencing, is common in basal-like and luminal B breast cancer,
and contributes to resistance to chemotherapy-induced apoptosis. Our own published data and the preliminary
data in this application support a role for DUSP4 as a mediator of drug resistance in breast cancer, and
suggest that genetic or epigenetic DUSP4 loss may be a therapeutically exploitable molecular alteration within
the tumor cell. Therefore, in line with these data I will explore two overarching scientific aims; 1) to determine
the mechanism by which DUSP4 loss inhibits chemotherapy-induced apoptosis and how this can be
circumvented, and 2) to use high-throughput siRNA screening for >7,500 gene targets in isogenic cell lines
which lack or express DUSP4 in order to identify synthetic lethal targets in breast cancers with DUSP4 loss.
The completion of the scientific aims of this proposal will develop my research skills in experimental models of
breast cancer while also developing the rationale for clinical trials to overcome therapeutic resistance in
DUSP4-deficient breast cancer. Finally, this proposal seeks identify novel therapeutic targets which could
impact breast cancer treatment.
项目摘要/摘要
《独立职业发展之路》提案的目标是请求对培训提供支持
发展乳腺癌实验模型方面的专业知识,同时解决知识的根本差距
这可能会对乳腺癌患者的治疗产生重大影响。在此期间提供K99/R00支持
我职业生涯的过渡阶段将是我作为一名独立调查员成功发展不可或缺的一部分
一家顶级研究机构。本文概述的培训计划将利用广泛的资源
在范德比尔特大学提供,以及拥有卓越科学记录的关键高级人员
充当导师和合作者。
作为我独立之路的一部分,我在范德比尔特组建了一个指导团队,为我的职业生涯
发展建议和科学方向。由Vanderbilt提供的教学研讨会、讲座和工作坊
生物研究教育和培训(BRET)办公室将为此提供有组织的支持
并将帮助我为独立教职做好进一步的准备。由提供的技术研讨会
杰克逊人类癌症实验模型实验室和两个生物信息学研讨会将
在本提案的较早阶段采取行动,以增进关于
基因工程小鼠模型和扩展我在生物信息学方面的专业知识和技能,这两个主要
本文概述的工作特点。
这项建议的科学部分集中在实验和机械测试的潜在作用
DUSP4在乳腺癌耐药中的作用DUSP4是一种双特异性磷酸酶,具有
针对MAPK通路的关键信号成分ERK1/2和JNK1/2的活性。我们之前已经
研究表明,DUSP4缺失,部分是由于表观遗传沉默,在基底细胞样癌和腔性B型乳腺癌中很常见,
并有助于抵抗化疗诱导的细胞凋亡。我们自己公布的数据和初步的
本申请中的数据支持DUSP4作为乳腺癌耐药的介体的作用,以及
提示遗传性或表观遗传性DUSP4缺失可能是一种治疗上可利用的分子改变
肿瘤细胞。因此,根据这些数据,我将探索两个最重要的科学目标:1)确定
DUSP4缺失抑制化疗诱导的细胞凋亡的机制及其机制
绕过,以及2)使用高通量siRNA筛选等基因细胞系中的7,500个基因靶点
它们缺失或表达DUSP4,以便在DUSP4缺失的乳腺癌中识别合成的致死靶点。
这项建议的科学目标的完成将培养我在实验模型中的研究技能
乳腺癌的同时也为临床试验克服治疗耐药性提供了理论基础
DUSP4缺陷型乳腺癌。最后,这项提议寻求确定新的治疗靶点,这些靶点可以
影响乳腺癌的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Justin M Balko其他文献
Justin M Balko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Justin M Balko', 18)}}的其他基金
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis
免疫检查点抑制剂相关心肌炎的免疫学和抗原驱动因素
- 批准号:
10618791 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis
免疫检查点抑制剂相关心肌炎的免疫学和抗原驱动因素
- 批准号:
10386891 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis
免疫检查点抑制剂相关心肌炎的免疫学和抗原驱动因素
- 批准号:
10219907 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
(PQ8) 患者和肿瘤特异性生物标志物和预测检查点抑制引起的 irAE 的机制
- 批准号:
9891975 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
(PQ8) 患者和肿瘤特异性生物标志物和预测检查点抑制引起的 irAE 的机制
- 批准号:
10590676 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
(PQ8) 患者和肿瘤特异性生物标志物和预测检查点抑制引起的 irAE 的机制
- 批准号:
10133451 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
(PQ8) 患者和肿瘤特异性生物标志物和预测检查点抑制引起的 irAE 的机制
- 批准号:
10359717 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
Dusp4 在乳腺癌中的作用:肿瘤抑制生物学和治疗策略
- 批准号:
8765222 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
Dusp4 在乳腺癌中的作用:肿瘤抑制生物学和治疗策略
- 批准号:
9268419 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
Dusp4 在乳腺癌中的作用:肿瘤抑制生物学和治疗策略
- 批准号:
9061648 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Research Grant